We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TSLA:NASDAQTesla, Inc. Analysis

Data as of 2026-08-30 - not real-time

$348.75

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind Tesla, Inc. is bearish at $348.75, with short-term averages lagging the long-term ones. Across the trailing 30 sessions it lost 8.4%. With RSI at 50.9 the momentum picture is neutral, alongside a bullish MACD signal. Recent trading has carved out support near $310.43 and resistance around $366.50.
Valuation screens as overvalued, on a P/E of 332.1 with no clean sector comparison available. Consensus targets land 11.9% above where the shares trade now. Revenue is growing at 25.5% on a 3.7% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 59.3%, a beta of 2.25 and a maximum drawdown of 39.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top Market Events

On August 18, 2026, Einride AB NASDAQ:ENRD said that it will add 500 Tesla, Inc.On August 17, 2026, Reuters reported, citing the Information, that Tesla Inc.Tesla is down 23% for the year yet Robotaxi is expanding, Cybercab production has started, and Optimus lines are being...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 400.93
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 400.93
  • Analyst targets imply +11.9% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • Analyst targets imply +11.9% versus the current price
  • Revenue growth of +25.5%
  • P/E ratio of 332.1

Key Metrics & Analysis

Financial Health

Revenue Growth25.50%
Profit Margin3.67%
P/E Ratio332.1
ROE4.67%
ROA1.93%
Debt/Equity18.37
P/B Ratio15.9
Op. Cash Flow$18.7B
Free Cash Flow$4.8B

Technical Analysis

TrendBearish
RSI50.9
Support$310.43
Resistance$366.50
MA 20$338.82
MA 50$360.47
MA 200$400.93
MACDBullish
VolumeStable
Fear & Greed Index95.66

Valuation

Fair Value$49.84
Target Price$390.09
Upside/Downside11.85%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.25
Volatility59.35%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.